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Summary
Introduction: In order to explore the mechanism of action of valproate (VPA) in
idiopathic generalized epilepsy (IGE), the effect of VPA on cortical EEG activity was
investigated. Hypothesis: VPA decreases EEG synchronization in the delta and theta
frequency bands in a use-dependent manner in IGE patients.
Methods: First setting: EEG records of 17 untreated IGE patients (NAE group) were
analyzed and compared to those of 15 healthy controls (NC group). Second setting: EEG
recorded in the untreated condition (NAE) was compared to the EEG recorded in the
treated condition (VPA) of the patient group. Technique and analysis: 2 min of eyes-
closed, waking EEG background activity (without epileptiform potentials and artifacts)
were analyzed. Absolute power (AP) and mean frequency (MF) were computed for 19
electrodes and four frequency bands (d = 1.5—3.5 Hz, u = 3.5—7.5 Hz, a = 7.5—12.5 Hz,
b = 12.5—25.0 Hz). Log-transformed data entered further analysis. Group differences
were computed by means of parametric statistics including correction for multiple
comparisons. The VPA-related changes (APvpa  APnae) were correlated with the
degree of the baseline abnormality (APnae) and the daily dose/serum levels of VPA.
Main results: Statistically significant (p < 0.05, corrected) changes in the first setting:
diffuse delta, theta, alpha AP increase, mainly right hemispheric beta AP increase was
found in the NAE group, as compared to the NC group. Second setting: VPA decreased
delta and theta AP. Strong correlation was demonstrated between the degree of the
initial AP abnormality and the VPA-related AP decrease. AP decrease did not correlate
with the daily dose and the serum level of the drug.
Conclusion: The hypothesis that VPA decreased EEG synchronization in the delta and
theta frequency bands in a use-dependent manner was supported. The findings
contribute to the understanding of the action of VPA at the network level.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Tel.: +36 52 511 777; fax: +36 52 511 729.
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Valproate decreases EEG synchronization 225Introduction
Valproate (VPA) is a widely used antiepileptic drug
that is effective in most epilepsy syndromes. The
efficacy of VPA against focal seizures is well
explained by its Na+ channel blocking property
and the consecutive decrease of repetitive neuronal
firing.1 On the other hand, the mechanism of action
of VPA against absences and myoclonic seizures
remains enigmatic. The electrographic patterns of
the latter seizures are generalized, bilaterally syn-
chronous spike-wave (GSW) paroxysms. The Na+
channel blocking property of VPA cannot explain
its efficacy against GSW-type seizures. Chiefly Na+
channel blocker drugs like carbamazepine and phe-
nytoin do not control these seizures in the experi-
mental setting2 and in humans. Instead, they
frequently aggravate absences and myoclonia in
patients with idiopathic generalized epilepsy,
IGE.3 Decreasing the thalamic T-Ca2+ currents was
suggested as the mechanism of the antiabsence
effect of VPA. Actually, this effect was demon-
strated in peripheral ganglion neurons of the rat,4
but was not found in thalamic neurons.5 The latter
finding is hardly compatible with the T-Ca2+ theory
of the antiabsence effect of VPA. Albeit some
further theories were created in the past two dec-
ades, the state of art is that none of the established
subcellular and molecular effects of VPA explains its
efficacy against GSW-type seizures.6
A likely cause of this uncertainty is that drug
actions established in neuronal preparations cannot
always explain changes at the network level.7 In
harmony with this statement, neuroscientists
recommended the investigation of intact brains as
the preferable approach to ‘‘global brain functions
and . . . paroxysmal activities’’.8 There is no doubt
that generalized seizures and their modification or
abolition belong to this category of events. Thus,
assessing the effect of VPA on network-generated
electromagnetic brain activity might be an alter-
native approach to explore the effect of the drug on
the central nervous system. The core element of IGE
pathophysiology is abnormally synchronized bio-
electric activity across a wide frequency range
(see below) in thalamo-cortical and cortico-cortical
networks.9—11 As to avoid confusion, hereunder the
term ‘‘synchronization’’ refers to simultaneous acti-
vation of great synaptic masses in the cortex as
recorded at a large spatial scale.12 Most striking
expressions of increased synchronization are the
2.5—6 Hz ictal and interictal GSW paroxysms in
the EEG records of IGE patients. However, spectral
analysis revealed that increased synchronization in
the 0.5—100 Hz frequency range is permanently
present in the interictal state, too. This means thatit was demonstrated in epochs of interictal back-
ground activity without GSW paroxysms.13—15
In a preliminary study we demonstrated that
decreased seizure propensity was accompanied by
decreased EEG synchronization in the delta and
theta frequency bands in IGE patients.16 However,
the methods used in that study did not allow the
detailed description of the drug-related changes.
The aim of the present study was to investigate the
effect of chronic VPA treatment on EEG synchroni-
zation in the 1.5—25 Hz frequency range at the
network level. In particular, we tested the hypoth-
esis that VPA decreases pathological synchronization
in the delta and theta bands in a use-dependent
manner in IGE patients. Use-dependent action is a
principle in pharmacology indicating that the mag-
nitude of the drug effect is proportional to the
degree of the baseline pathophysiological abnorm-
ality. While the use-dependent dynamics of the Na+
channel blocking effect of VPA is well-known,1 the
dynamics of the VPA effect at the network level has
not been investigated yet. Our hypothesis was built
on the above listed pieces of evidence with special
reference to the VPA-related EEG normalization of
background activity,16,17 and, by analogy, the use-
dependent action of another antiabsence drug,
lamotrigine, on EEG synchronization in IGE
patients.18Patients and methods
The study design was approved by the Local
Research Ethics Committee of Kene´zy Gyula Hospi-
tal. The patients were diagnosed and treated as
usual. No diagnostic procedure or treatment was
indicated, missed, or postponed for study purposes.
Inclusion criteria were: unmedicated IGE patients,
who were referred to the Epilepsy Center and ful-
filled the diagnostic criteria for ‘‘IGE with variable
phenotypes’’19; age of onset after the eighth year of
age; the presence of absences and/or myoclonic
seizures. Exclusion criteria were: any medication
except oral contraceptives, alcohol or drug abuse;
any medical condition that is known to influence
EEG activity; generalized tonic—clonic seizure in the
5 days before EEG investigation. Neurological and
EEG investigations were done at the first visit. VPA
monotherapy started the next day with an 500 mg
evening dose of the same, controlled release pro-
duct. In addition, regular sleep and life style was
recommended. If the seizures persisted the daily
dose was progressively increased until seizure con-
trol was reached. The patients recorded the date of
seizures and the adverse events in their seizure
diary. The second EEG was done 3 months after
226 B. Clemensthe first EEG, because initial, transient EEG effects
of the drug disappear by the 90th day of treat-
ment.20 By this time all the patients (11 females,
6 males; age limits: 16 and 31 years average: 19.4
years) were seizure-free, and no patient experi-
enced symptoms or complaints indicating adverse
effects of the drug. The daily dose of VPA was in the
500—1500 mg range, serum levels (determined in
the morning, just before of the second EEG inves-
tigation) were within the therapeutic range. The
normal control group (NC) was composed of 15
healthy persons (10 females, 5 males, age limits:
16 and 32 years, average: 21.9 years). The age
difference between the two groups was statistically
not significant (unpaired t-test, p > 0.05). The EEG
data of the NC group were used as normative refer-
ence, facilitating the proper interpretation of the
drug-related changes on the normality—abnormality
axis.
EEG recording and data analysis
All recordings were carried out in the morning, after
a night of sufficient sleep, in the same semi-isolated
room, with the same Brain Quick (Micromed SRL,
Mogliano Veneto, Italy) digital equipment, by
trained personnel, according to recommended stan-
dards for quantitative EEG studies.21 Silver-silver
chloride electrodes were placed according to the
10-20 system, fixed by appropriate adhesive and
conductive gel. Impedances did not exceed 5 kV.
Nineteen-channel EEG was recorded against linked
ears reference. Additional bipolar derivations were
used to differentiate between EEG and eye move-
ments potentials, and to detect EMG activity. In the
EEG derivations the filters were set at 0.1 and 30 Hz.
Sampling frequency was 128 s1. Twelve-bit on-line
digitization was used. Thirty minutes EEG was
recorded in waking-relaxed, eyes-closed condition.
The first 2 min of artifact-free editable EEG activity
(sixty 2-s epochs) were selected for quantitative
EEG analysis. Our standard epoch selection protocol
includes: (1) the presence of continuous physiolo-
gical waking alpha activity with alpha voltage max-
imum in posterior regions, (2) the absence of
artifacts, epileptiform potentials, and other non-
stationary elements, and (3) the absence of patterns
indicating drowsiness or arousal. Epoch selection
was done blindly, without knowing the person’s
name and condition.
After final visual revision of the edited epochs they
were processed by the Neurometric Analysis system
software, Version 2.80. Fast Fourier transform-
derived data were used to compute absolute power
(AP; microvolts squared) and mean frequency (MF;
Hz) for the 19 derivations and four frequency bands(d = 1.5—3.5 Hz, u = 3.5—7.5 Hz, a = 7.5—12.5 Hz,
b = 12.5—25.0 Hz). Leakage was reduced by Hanning
window. As to approximate Gaussian distribution the
raw data were logarithmically transformed. The
transformed data entered group analysis. In the first
setting the group of untreated patients (NAE) was
compared to the normal control group (NC) by t-tests
for independent datasets. In the second setting the
untreated (NAE) and treated (VPA) conditions of the
patients were compared by t-tests for interdepen-
dent datasets. The probability of type-I errors inher-
ent to multiple comparisons was reduced by
Bonferroni’s corrections in both settings. Corrected
p < 0.05 differences were accepted as statistically
significant. In addition, VPA-related changes of band
power (APvpa  APnae)were compared between the
averagesof the lateral (F7,T3,T5,F8,T4,T6)and the
medial (the 3 midline + 10 parasagittal) electrode
sites by t-tests for interdependent datasets.
Correlation between the variables was computed
by the nonparametric (Spearman) method for math-
ematical reasons. The relationship between the
VPA-related AP changes (APvpa  APnae) and the
baseline abnormality (APnae) was evaluated for all
bands and electrodes. Also the correlation between
the VPA-related AP changes and the daily dose and
serum levels of VPA was investigated. For the latter
correlations p < 0.05 (uncorrected) values were
accepted as statistically significant.Results
Tables 1 and 2 show the raw data that reflect the
original magnitude  S.D. of the quantitative EEG
variables and are more comfortable to the reader
than the log-transformed values. The p-values were
derived from the comparison of the log-transformed
values.
NAE versus NC comparison
The mean finding was the overall excess of absolute
power in the untreated IGE patients (Table 1). Delta
and theta AP were about two to four times higher in
the NAE than in the NC group, and the differences
were statistically significant ( p < 0.001 in all deri-
vations). Also alpha AP was increased in the NAE
group; however, the p-values suggested that the
deviation from the normative data (NC) is less
marked. Beta AP increase was moderate and asym-
metrical.
The range of the MF differences was <0.1 Hz for
delta;<0.2 Hz for theta;<0.5 Hz for alpha;<0.2 Hz
for beta. Thus, MF differences were small and sta-
tistically not significant in most (72/76) cases.
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Table 1 Comparison of the untreated patients (nae) and the normal controls (nc)
Absolute
power
Fp1 Fp2 F3 F4 C3 C4 P3 P4 O1 O2 F7 F8 T3 T4 T5 T6 Fz Cz Pz Average
DELTAnae 15.11 16.03 19.87 21.34 24.48 27.44 33.78 32.66 32.01 36.32 11.41 11.19 11.65 10.96 25.54 24.83 23.67 33.37 44.19 23.99
S.D. 8.49 9.23 11.94 10.85 20.56 22.50 32.79 26.83 24.51 28.53 5.81 6.13 6.86 5.62 21.14 18.21 14.89 30.06 50.34 16.84
DELTAnc 5.78 6.13 8.51 9.07 9.19 9.69 9.63 8.79 7.76 8.11 4.62 4.45 4.58 4.21 6.43 5.69 10.69 12.09 12.10 7.76
S.D. 2.39 2.89 4.68 4.66 4.01 4.20 4.12 4.28 3.02 4.15 2.07 2.15 2.17 2.16 3.17 3.22 5.83 5.16 5.08 3.29
p *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** ** *** *** ***
THETAnae 25.59 27.28 42.10 46.16 47.41 53.67 55.63 57.01 49.30 55.85 21.43 20.86 19.80 21.53 40.93 38.85 53.30 68.17 79.88 43.41
S.D. 21.10 24.18 38.23 44.15 46.70 47.37 54.46 48.07 51.63 65.30 16.82 18.86 15.84 17.63 47.18 36.83 52.10 68.12 84.82 38.56
THETAnc 5.78 5.90 11.44 11.65 12.22 12.79 11.48 11.03 7.71 8.21 5.23 4.74 5.45 4.89 6.90 5.85 13.90 16.09 14.30 9.24
S.D. 3.05 3.27 7.21 6.57 7.36 7.75 6.56 7.00 3.52 4.44 2.62 2.67 3.01 3.16 3.25 3.66 8.40 10.07 7.72 4.84
p *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** ***
ALPHAnae 39.29 40.46 58.13 60.45 66.64 76.14 122.70 123.70 212.00 226.80 30.87 28.55 30.20 31.41 103.10 119.60 70.90 92.67 157.80 89.02
S.D. 25.92 25.22 36.94 37.87 38.04 41.89 78.05 68.27 181.20 193.00 20.92 16.58 18.36 16.42 76.62 93.39 47.74 58.71 96.27 48.26
ALPHAnc 13.54 13.41 20.70 21.81 28.06 29.57 42.89 37.08 59.62 67.26 10.92 10.46 11.38 9.94 30.22 26.67 25.17 36.11 62.04 29.31
S.D. 9.45 8.83 11.04 11.84 17.97 20.88 32.96 25.39 47.26 53.49 7.45 6.72 6.82 6.20 27.74 16.28 14.00 27.81 45.97 16.21
p ** ** * ** * ** ** *** *** ** ** ** * ** *** *** * * * **
BETAnae 10.50 10.97 16.17 16.43 16.34 17.28 20.27 19.17 24.43 25.54 9.23 8.09 9.51 8.68 17.06 15.28 17.14 20.48 23.64 16.12
S.D. 6.66 7.28 10.47 8.96 10.35 9.76 14.31 11.06 18.69 22.86 6.28 4.40 6.55 5.17 15.78 10.41 10.60 12.87 16.63 10.00
BETAnc 5.33 5.03 8.36 7.69 8.81 8.48 9.01 8.47 9.17 9.34 5.09 4.05 4.92 3.99 7.49 5.89 8.68 9.70 10.72 7.38
S.D. 2.76 2.29 4.16 3.59 4.44 4.00 4.53 4.52 6.69 6.76 2.75 2.12 2.83 1.79 4.10 3.33 4.04 4.58 5.50 3.29
p ns * ns * ns ns * ** ** ** ns ns ns * ns ** ns ns * *
Mean
frequency
Fp1 Fp2 F3 F4 C3 C4 P3 P4 O1 O2 F7 F8 T3 T4 T5 T6 Fz Cz Pz Average
DELTAnae 2.38 2.37 2.41 2.39 2.38 2.38 2.36 2.37 2.38 2.39 2.41 2.40 2.38 2.39 2.37 2.38 2.40 2.40 2.37 2.38
S.D. 0.06 0.04 0.05 0.03 0.06 0.06 0.07 0.06 0.07 0.07 0.06 0.04 0.06 0.05 0.08 0.06 0.04 0.05 0.06 0.04
DELTAnc 2.31 2.32 2.36 2.37 2.37 2.37 2.36 2.36 2.34 2.34 2.34 2.35 2.36 2.35 2.37 2.35 2.37 2.38 2.36 2.35
S.D. 0.06 0.04 0.06 0.05 0.05 0.05 0.04 0.04 0.05 0.04 0.07 0.07 0.07 0.07 0.06 0.05 0.06 0.06 0.04 0.03
p * ns ns ns ns ns ns ns ns ns ** ns ns ns ns ns ns ns ns ns
THETAnae 5.59 5.57 5.65 5.63 5.65 5.65 5.68 5.67 5.61 5.57 5.57 5.57 5.58 5.61 5.62 5.62 5.65 5.65 5.67 5.62
S.D. 0.19 0.18 0.20 0.20 0.19 0.19 0.19 0.22 0.20 0.21 0.21 0.18 0.19 0.19 0.19 0.23 0.20 0.21 0.25 0.18
THETAnc 5.51 5.50 5.52 5.52 5.51 5.51 5.50 5.51 5.44 5.48 5.46 5.49 5.45 5.48 5.47 5.50 5.51 5.49 5.48 5.49
S.D. 0.16 0.19 0.15 0.18 0.20 0.17 0.22 0.21 0.22 0.24 0.16 0.18 0.18 0.17 0.25 0.23 0.16 0.20 0.23 0.18
p ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns
ALPHAnae 9.46 9.48 9.43 9.44 9.42 9.42 9.51 9.49 9.75 9.77 9.46 9.49 9.48 9.45 9.57 9.55 9.42 9.38 9.49 9.50
S.D. 0.41 0.42 0.40 0.42 0.39 0.40 0.47 0.49 0.44 0.43 0.39 0.41 0.35 0.41 0.44 0.48 0.43 0.44 0.51 0.41
ALPHAnc 9.74 9.75 9.69 9.67 9.80 9.73 9.98 9.94 10.21 10.24 9.74 9.74 9.79 9.76 10.02 10.06 9.65 9.75 10.02 9.86
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1.NAE versus VPA comparison
The main result of this comparison was the overall
decrease of AP in the treated condition as compared
to the untreated one (Table 2). AP values in the
treated patients took intermediate positions
between the NC and NAE results. Delta AP differ-
ences were statistically significant in all derivations
over the right hemisphere but only in two deriva-
tions over the left one. Theta AP differences were
statistically significant at all electrode sites, except
two, left hemispheric derivations. Comparing the p-
values at the mirror electrode sites suggested that
the right hemispheric theta differences are more
marked than their left hemispheric counterparts.
Alpha and beta AP decreased in all derivations but
the differences were statistically not significant
except for alpha AP in a single derivation.
The VPA-related decrease of power was more
marked in the medial than in the lateral derivations.
However, medial-lateral differences were statisti-
cally significant only for the delta ( p = 0.0019) and
theta ( p = 0.0080) bands.
The correlation coefficients suggested a strong
relationship between the decrease of AP (APv-
pa  APnae) and the degree of the initial abnorm-
ality (APnae) in all derivations and frequency
bands: the higher the initial APnae value, the
greater the VPA-related AP decrease (Table 3). An
illustrative example is given in Fig. 1. The coeffi-
cient of determination, ‘‘r squared’’22 was in the
range of 0.30—0.90, suggesting a considerable
biological interrelatedness.
MF changes were small and statistically not sig-
nificant in all bands and derivations. However, the
consistency of the electrode-related changes con-
cerning magnitude and direction of the changesFigure 1 Correlation between right frontal (F4) delta
power in the untreated state (APnae) and the drug-related
decrease of AP (APvpa  APnae). Each dot represents one
patient. Correlation coefficient = 0.78; p = 0.0002.
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Table 2 Comparison of the untreated (nae) and treated (vpa) conditions of the patients
Absolute
power
Fp1 Fp2 F3 F4 C3 C4 P3 P4 O1 O2 F7 F8 T3 T4 T5 T6 Fz Cz Pz Average
DELTAnae 15.11 16.03 19.87 21.34 24.48 27.44 33.78 32.66 32.01 36.32 11.41 11.19 11.65 10.96 25.54 24.83 23.67 33.37 44.19 23.99
S.D. 8.49 9.23 11.94 10.85 20.56 22.50 32.79 26.83 24.51 28.53 5.81 6.13 6.86 5.62 21.14 18.21 14.89 30.06 50.34 16.84
DELTAvpa 9.46 8.66 13.57 13.32 15.20 14.70 19.57 18.72 24.42 24.55 8.35 6.12 8.33 5.90 16.35 15.31 15.07 18.28 23.74 14.72
S.D. 4.64 4.31 6.11 6.45 6.63 7.20 11.49 13.11 22.59 28.87 4.24 3.21 4.01 3.18 12.55 11.51 7.06 8.21 15.02 8.33
p ** *** ns * ns ** * ** ns * ns *** ns *** ns * ns ** ** *
THETAnae 25.59 27.28 42.10 46.16 47.41 53.67 55.63 57.01 49.30 55.85 21.43 20.86 19.80 21.53 40.93 38.85 53.30 68.17 79.88 43.41
S.D. 21.10 24.18 38.23 44.15 46.70 47.37 54.46 48.07 51.63 65.30 16.82 18.86 15.84 17.63 47.18 36.83 52.10 68.12 84.82 38.56
THETAvpa 13.65 12.13 22.16 21.48 25.32 25.02 29.59 26.24 32.33 29.79 12.73 9.26 12.65 8.71 22.77 17.67 24.53 31.97 39.54 21.98
S.D. 9.70 8.93 13.68 13.95 16.33 18.34 19.46 19.91 30.73 28.35 8.86 6.84 8.41 7.32 19.41 12.25 15.89 22.92 30.87 15.23
p ** *** * ** * *** * *** ns ** * *** ns *** * *** *** *** ** **
ALPHAnae 39.29 40.46 58.13 60.45 66.64 76.14 122.70 123.70 212.00 226.80 30.87 28.55 30.20 31.41 103.10 119.60 70.90 92.67 157.80 89.02
S.D. 25.92 25.22 36.94 37.87 38.04 41.89 78.05 68.27 181.20 193.00 20.92 16.58 18.36 16.42 76.62 93.39 47.74 58.71 96.27 48.26
ALPHAvpa 27.80 24.61 40.35 38.10 52.40 48.62 100.40 96.82 179.30 181.00 23.48 16.56 23.86 16.51 77.11 106.90 44.44 62.69 129.20 67.91
S.D. 18.21 16.46 23.85 22.62 33.58 31.84 59.11 57.96 127.90 135.20 16.40 10.58 13.96 11.90 51.33 143.30 26.45 45.04 82.74 36.98
p ns ns ns ns ns ns ns ns ns ns ns ns ns * ns ns ns ns ns ns
BETAnae 10.50 10.97 16.17 16.43 16.34 17.28 20.27 19.17 24.43 25.54 9.23 8.09 9.51 8.68 17.06 15.28 17.14 20.48 23.64 16.12
S.D. 6.66 7.28 10.47 8.96 10.35 9.76 14.31 11.06 18.69 22.86 6.28 4.40 6.55 5.17 15.78 10.41 10.60 12.87 16.63 10.00
BETAvpa 8.71 8.18 13.44 13.25 14.64 13.91 18.02 15.62 23.34 22.35 8.30 5.92 8.82 5.91 15.79 13.23 13.92 16.81 20.42 13.71
S.D. 4.59 4.78 7.47 7.31 8.74 7.90 10.17 8.70 17.98 23.37 4.77 3.50 5.20 3.44 12.08 11.06 8.32 10.16 12.03 7.87
p ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns
Mean
frequency
Fp1 Fp2 F3 F4 C3 C4 P3 P4 O1 O2 F7 F8 T3 T4 T5 T6 Fz Cz Pz Average
DELTAnae 2.38 2.37 2.41 2.39 2.38 2.38 2.36 2.37 2.38 2.39 2.41 2.40 2.38 2.39 2.37 2.38 2.40 2.40 2.37 2.38
S.D. 0.06 0.04 0.05 0.03 0.06 0.06 0.07 0.06 0.07 0.07 0.06 0.04 0.06 0.05 0.08 0.06 0.04 0.05 0.06 0.04
DELTAvpa 2.37 2.36 2.39 2.39 2.39 2.38 2.38 2.36 2.37 2.36 2.39 2.37 2.40 2.36 2.38 2.35 2.40 2.39 2.37 2.38
S.D. 0.05 0.06 0.06 0.05 0.06 0.05 0.06 0.07 0.08 0.08 0.05 0.05 0.06 0.05 0.06 0.07 0.05 0.06 0.06 0.05
p ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns
THETAnae 5.59 5.57 5.65 5.63 5.65 5.65 5.68 5.67 5.61 5.57 5.57 5.57 5.58 5.61 5.62 5.62 5.65 5.65 5.67 5.62
S.D. 0.19 0.18 0.20 0.20 0.19 0.19 0.19 0.22 0.20 0.21 0.21 0.18 0.19 0.19 0.19 0.23 0.20 0.21 0.25 0.18
THETAvpa 5.56 5.55 5.57 5.58 5.59 5.60 5.62 5.62 5.55 5.55 5.52 5.54 5.50 5.55 5.54 5.59 5.57 5.59 5.65 5.57
S.D. 0.17 0.16 0.17 0.16 0.19 0.20 0.19 0.23 0.21 0.22 0.17 0.16 0.18 0.19 0.19 0.24 0.17 0.20 0.24 0.18
p ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns
ALPHAnae 9.46 9.48 9.43 9.44 9.42 9.42 9.51 9.49 9.75 9.77 9.46 9.49 9.48 9.45 9.57 9.55 9.42 9.38 9.49 9.50
S.D. 0.41 0.42 0.40 0.42 0.39 0.40 0.47 0.49 0.44 0.43 0.39 0.41 0.35 0.41 0.44 0.48 0.43 0.44 0.51 0.41
ALPHAvpa 9.61 9.63 9.59 9.60 9.58 9.58 9.72 9.75 9.92 9.95 9.63 9.64 9.65 9.65 9.79 9.79 9.59 9.54 9.71 9.68
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1.(decrease in theta MF, increase in alpha and beta
MF) should be noted.
Other results
Correlation coefficients between the daily doses of
VPA and AP decrease (r = 0.23, p > 0.05), and
between serum levels of VPA and AP decrease
(r = 0.19, p > 0.05) indicated that the AP-decreas-
ing effect of VPA is neither dose-dependent nor
serum level dependent.Discussion
Despite the efforts of pharmacological research the
molecular-subcellular mechanism of action of VPA
against GSW-type seizures remains enigmatic.6 In
this study we used an alternative approach and tried
to grasp the net effect of VPA on the cerebral cortex,
the structure that plays the main role in generating
seizures. The scientific rationale of the EEG
approach is that IGE and its pathophysiology can
be properly characterized in terms of disturbed
bioelectric activity. Scalp EEG reflects EEG dynamics
at a large spatial scale, allowing the quantitative
assessment of network-generated, synchronized
activities.23 Within this framework, AP reflects
the degree of synchronization of the cortical EEG
sources at a given frequency (or, in a frequency
band), and is proportional to the number of the
synchronously activated generators that contribute
to the signal.24 MF changes (in particular, the
decrease of MF) usually indicate diffuse cortical
lesions or metabolic derangement of the cortex
and its neuronal interconnections. Thus, VPA-
related delta and theta AP changes without signifi-
cant MF shifts indicate the ‘‘pure’’ decrease of
synchronization in these frequency bands, without
altered tuning of the selectively distributed neuro-
nal networks that are the anatomical basis of the
normal EEG rhythms.25
The use-dependent action of VPA on
synchronization
In the NC versus NAE comparison we confirmed that
the main bioelectric abnormality of IGE is increased
synchronization at the thalamo-cortical level of the
brain.14,15,17 The abnormality was particularly
marked in the delta and theta bands.
The selective or, preferential effect of VPA on
pathological but not normal network activity was
first suggested by an evoked potential study. VPA
normalized abnormally large-amplitude visual
evoked potentials in patients with photosensitive
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Table 3 Correlation between absolute power in the untreated condition (APnae) and VPA-related decrease of power
(APvpa  APnae)
Derivation rd p ru p ra p rb p
Fp1 0.78 *** 0.86 *** 0.7 ** 0.63 **
Fp2 0.84 *** 0.83 *** 0.72 ** 0.75 ***
F3 0.79 *** 0.83 *** 0.74 *** 0.74 ***
F4 0.78 *** 0.81 *** 0.72 ** 0.71 **
C3 0.83 *** 0.71 ** 0.75 *** 0.67 **
C4 0.84 *** 0.78 *** 0.78 *** 0.76 ***
P3 0.85 *** 0.71 ** 0.74 *** 0.75 ***
P4 0.94 *** 0.8 *** 0.79 *** 0.71 **
O1 0.55 * 0.56 * 0.68 ** 0.58 *
O2 0.68 ** 0.6 ** 0.68 ** 0.56 *
F7 0.81 *** 0.88 *** 0.68 ** 0.64 **
F8 0.84 *** 0.81 *** 0.74 *** 0.69 **
T3 0.72 ** 0.78 *** 0.8 *** 0.65 **
T4 0.95 *** 0.86 *** 0.69 ** 0.73 ***
T5 0.69 ** 0.82 *** 0.89 *** 0.76 ***
T6 0.68 ** 0.86 *** 0.6 * 0.52 *
Fz 0.82 *** 0.85 *** 0.75 *** 0.77 ***
Cz 0.77 *** 0.76 *** 0.72 ** 0.8 ***
Pz 0.87 *** 0.84 *** 0.76 *** 0.77 ***
r = correlation coefficient. *p < 0.05; **p < 0.01; ***p < 0.001.epilepsy but did not affect the normal responses of
healthy persons.26 An investigation carried out in
IGE patients disclosed the selectivity of the VPA
effect in terms of frequency bands: the drug
decreased spectral power only in the bands (delta,
theta, and, to a lesser degree, alpha) where power
had been pathologically increased in the untreated
condition.16 Topographic selectivity was reported in
another paper: VPA normalized Omega-complexity
(a linear measure of spatial synchrony) only in the
anterior part of the cortex where this measure had
been pathologically altered in the untreated
state.17
Ourpresent results support theearlier findings and
the idea of the selective action of VPA on abnormal
EEG activity. First, the quantitative EEG variables
that reflect the activity of anatomically and physio-
logically diverse neuronal mechanisms were influ-
enced disparately. VPA significantly decreased AP
that had been pathologically increased in the
untreated condition but did not affect MF that had
been near normal in the untreated patients. Second,
VPA decreased (normalized) synchronization in the
delta and theta bands that had beenmarkedly abnor-
mal in the untreated condition but did not signifi-
cantly decrease synchronization in the alpha and
beta bands where the baseline abnormality had been
less marked.
A novel finding is that the VPA-related decrease
of synchronization was significantly greater in the
medial (midline + parasagittal) leads than in the
lateral derivations. The possible reason for thisdifference may be the different thalamic connec-
tivity of the medial and lateral cortical regions as
defined above. Roughly, the medial electrodes
mainly explore the frontal and parietal cortex
where the majority of the so-called non-specific
thalamo-cortical fibers terminate, mediating the
synchronized recruiting cortical response and the
spike-wave paroxysms.27 The network containing
the fronto-parietal cortex, the reticular and relay
nuclei of the thalamus and their interconnections is
the anatomical substrate of the generalized sei-
zures in the animal models of IGE.9,10 Thus, it is
not surprising that the effect of VPA was greater in
these areas than in the lateral cortex that only
receives the minority of the non-specific tha-
lamo-cortical fibers and plays an uncertain but
presumably minor (if any) role in the pathophysiol-
ogy of IGE. The fact that VPA caused significant
decrease of delta—theta synchronization also in
the lateral derivations might be explained by the
increased synchronization in the same frequency
range within the anatomically dense cortico-corti-
cal network, the synchronizing role of which has
been clearly demonstrated in IGEmodels.11 In addi-
tion, volume conduction might contribute to the
findings in the lateral derivations.12
An unexpected finding was the right hemispheric
preponderance of the VPA-related decrease of delta
and theta synchronization. However, the detailed
analysis and discussion of hemispheric asymmetry in
natural and drug-related conditions is beyond the
scope of this study.
232 B. ClemensThe above listed results of the NAE versus VPA
comparison strongly support the idea that VPA selec-
tively decreases synchronization in the cortical
compartment of the networks that are pathologi-
cally synchronized ictally and interictally. This over-
all conclusion was quantitatively refined by our
correlation studies. The other novelty of this study
is that the relationship between the drug’s action
and the degree of the baseline abnormality
(increased synchronization) was quantitatively
established. In other words, the use-dependent
action of VPA on EEG synchronization (as postulated
in our hypothesis) was demonstrated.
In theory, the daily dose and serum level of VPA
might co-determine the quantitative EEG changes.
The lack of meaningful correlation between the
decrease of synchronization and the pharmacologi-
cal data (daily dose and serum level of VPA) is in
accord with a prior paper reporting no correlation
between EEG spectral variables and serum levels of
VPA.28
The obvious shortcoming of this study is the lack
of a control group composed of age- and sex-
matched healthy persons. However, the exposure
of healthy people to an already marketed and not
entirely harmless drug (VPA) for study purposes was
hardly acceptable for ethical reasons. Pieces of
evidence suggest that our results are reliable even
in the absence of a control group. The results were
robust and statistically highly significant in both
settings, and the magnitude of the changes highly
exceeded the range of the test—retest variability of
the quantitative EEG parameters.29 The overall and
neurological condition of the patients was con-
trolled clinically, and the EEG environment and
procedure were always the same. Thus, disregard-
ing the effect of VPA, influences that significantly
alter the patients’ condition and confound the EEG
results in a systemic manner30 are highly improb-
able. Small changes in physiological parameters that
are by nature random-like cannot be excluded but
do not generate statistically highly significant dif-
ferences. Finally, the reported effect of VPA on EEG
synchronization in the 1.5—25 Hz frequency range is
not an obligatory reaction of the brain to VPA expo-
sure, because using the same study design (before
treatment versus on treatment) we did not observed
it in a group of migraine patients who received VPA
as prophylactic treatment (Clemens, unpublished
results).
The possible clinical relevance to the
findings
The search after electrophysiological markers
of seizure liability and seizure control has beenadvocated in an Editorial.31 From this perspective,
the possible clinical significance of our findings may
be inherent in the established relationship between
EEG synchronization, excitability of the cortex, and
seizure liability as discussed in several papers.32—34
Within this framework VPA-related decrease of syn-
chronization might be related to the decrease of
seizure propensity. In fact, the decrease of EEG
synchronization was associated with complete sei-
zure control in our patients. However, EEG normal-
ization should not be interpreted as a marker of
good therapeutic response for several reasons. In
addition to the synchronization of the cortical neu-
ronal mass, seizure liability and seizure control are
modified at subcortical sites,35 and influenced by
genetic factors.36 The relationship between
decreased synchronization and seizure control
should be investigated empirically, correlating indi-
vidual, VPA-related changes with clinical outcome
variables in a sufficient number of VPA-responder
and nonresponder IGE patients.References
1. Macdonald RL, McLean M. Anticonvulsant drugs: mechanisms
of action. In: Delgado-Escueta AV, Ward AA, Woodbury DM,
Porter RJ, editors. Basic mechanisms of the epilepsies.
Molecular and cellular approaches. New York: Raven Press;
1986. p. 713—36.
2. Zhang YF, Coulter DA. Anticonvulsant drug effect on spon-
taneous thalamocortical rhythms in vitro: phenytoin,
carbamazepine, and phenobarbital. Epilepsy Res 1996;23:
55—70.
3. Parker AP, Agathonikou A, Robinson RO, Panayiotopoulos CP.
Inappropriate use of carbamazepine and vigabatrin in typical
absence seizures. Dev Med Child Neurol 1998;40:517—9.
4. Kelly KM, Gross RA, MacDonald RL. Valproic acid selectively
reduces the low-threshold [T] calcium current in rat nodose
neurons. Neurosci Lett 1990;116:233—8.
5. Coulter DA, Huguenard JR, Prince DA. Characterization of
ethosuximide reduction of low-threshold calcium currents in
thalamic neurons. Ann Neurol 1989;25:582—93.
6. Lo¨scher W. Basic pharmacology of valproate. A review after
35 years of clinical use for the treatment of epilepsy. CNS
Drugs 2002;16:669—94.
7. Capek R, Esplin B. Mechanisms of anticonvulsant action of
valproate. An overview and perspective. In: Avoli M, Gloor P,
Kostopoulos G, Naquet R, editors. Generalised epilepsy.
Neurobiological approaches. Boston: Birkhauser; 1990. p.
436—59.
8. Steriade M. Impact of network activities on neuronal proper-
ties in corticothalamic systems. Am Physiol Soc 2001;86:
1—39.
9. Gloor P, Avoli M, Kostopoulos G. Thalamo—cortical relation-
ships in generalized epilepsy with bilaterally synchronous
spike-and-wave discharge. In: Avoli M, Gloor P, Kostopoulos
G, Naquet R, editors. Generalized epilepsy. Neurobiological
approaches. Boston: Birkhauser; 1990. p. 190—212.
10. Steriade M, Amzica F. Dynamic coupling among neocortical
neurons during evoked and spontaneous spike-wave seizure
activity. J Neurophysiol 1994;72:2051—69.
Valproate decreases EEG synchronization 23311. Steriade M, Contreras D. Relation between cortical and
thalamic cellular events during transition from sleep patterns
to paroxysmal activity. J Neurosci 1995;15:623—42.
12. Nunez PL. Quantitative states of neocortex. In: Nunez PL,
editor. Neocortical dynamics and human EEG rhythms.
Oxford University Press; 1995. p. 1—18.
13. Mirsky AF, Duncan CC. Behavioral and electrophysiological
studies of absence epilepsy. In: Avoli M, Gloor P, Kostopoulos
G, Naquet R, editors. Generalized epilepsy. Neurobiological
approaches. Boston: Birkhauser; 1990. p. 254—69.
14. Clemens B, Szigeti G, Barta Z. EEG frequency profiles of
idiopathic generalised epilepsy syndromes. Epilepsy Res
2000;42:105—15.
15. Willoughby JO, Fitzgibbon SP, Pope KJ, Mackenzie L, Medve-
dev AV, Clark CR, et al. Persistent abnormality detected in
the non-ictal electroencephalogram in primary generalized
epilepsy. J Neurol Neurosurg Psychiat 2003;74:51—5.
16. Clemens B, Barta Z. Valproate treatment normalises EEG
frequency profiles in idiopathic (primary) generalised epi-
lepsy. Clin Neurosci/Ideggy Szle 1999;52:307—17. [in Hun-
garian, English Abstract].
17. Kondakor I, Toth M, Wackermann J, Gyimesi C, Czopf J,
Clemens B. Distribution of spatial complexity of EEG in
idiopathic generalized epilepsy and its change after chronic
valproate therapy. Brain Topogr 2005;18:115—23.
18. Clemens B, Piros P, Bessenyei M, Hollo´dy K. Lamotrigine
decreases EEG synchronization in a use-dependent manner
in patients with idiopathic generalized epilepsy. Clin Neuro-
physiol 2007;118:910—7.
19. Panayiotopoulos C. Idiopathic generalized epilepsies. In:
Panayiotopoulos C, editor. The epilepsies. Seizures, syn-
dromes, and management. Springer; 2005. p. 271—348.
20. Sannita WG, Gervasio L, Zagoni P. Quantitative EEG effects
and plasma concentration of sodium valproate: acute and
long-term administration to epileptic patients. Pharmacoe-
lectroencephalography 1989;22:231—5.
21. Nuwer M, Lehmann D, Lopes da Silva F, Matsuoka S, Sutherling
W, Vibert JF. IFCN guidelines for topographic and frequency
analysis of EEGs and EPs. Report of an IFCN committee.
Electroencephal Clin Neurophysiol 1994;91:1—5.
22. Motulsky H. Intuitive biostatistics. Oxford University Press;
1995.
23. Nunez P. Toward a quantitative description of large-scale
neocortical dynamic function and EEG. Behav Brain Sci
2000;23:371—437.24. Pfurtscheller G, Lopes da Silva FH. Event-related EEG/MEG
synchronization and desynchronization: basic principles. Clin
Neurophysiol 1999;110:1842—57.
25. Basar E, Schu¨rmann M, Brain functioning: integrative mod-
els.Basar E, editor. Brain function and oscillations: Integra-
tive brain function Neurophysiology and cognitive processes,
vol. II. Springer; 1999. p. 393—406.
26. Harding GFA, Alford CA, Powell TE. The effect of sodium
valproate on sleep, reaction times, and visual evoked
potential in normal subjects. Epilepsia 1985;26:
597—601.
27. Morison RS, Dempsey EW. A study of thalamocortical rela-
tions. Am J Physiol 1942;135:281—92.
28. Sundquist A, Nilsson BY, Tomson T. Valproate monotherapy in
juvenile myoclonic epilepsy: dose-related effects on elec-
troencephalographic and other neurophysiological tests.
Ther Drug Monit 1999;21:91—6.
29. John ER, Prichep L, Ahn H, Easton P, Fridman J, Kaye H.
Neurometric evaluation of cognitive dysfunctions and
neurological disorders in children. Prog Neurobiol 1983;21:
290—329.
30. Sannita WG. Individual variability, end-point effects and
possible biases in electrophysiological research. Clin Neuro-
physiol 2006;117:2569—83.
31. Ebersole JS. The last word [Editorial]. J Clin Neurophysiol
1998;15:175—6.
32. Stefan H, Hoffmann F, Burr W, Fro¨scher W, Penin H. Wirk-
samkeit einer Valproinsa¨ure-Monotherapie auf Spike-wave
Aktivitat bei prima¨r generalisierten Epilepsien. Nervenarzt
1981;52:707—14.
33. van Gelder NM, Siatitsas I, Menini C, Gloor P. Feline general-
ised penicillin epilepsy: changes of glutamine acid and taurin
parallel to the progressive increase in excitability of the
cortex. Epilepsia 1983;24:200—13.
34. Kostopoulos G. Neuronal sensitivity to GABA and glutamate in
generalised epilepsy with spike and wave discharges. Exp
Neurol 1986;92:20—36.
35. Moshe´ SL, Sperber EF. Substantia nigra-mediated control of
generalized seizures. In: Avoli M, Gloor P, Kostopoulos G,
Naquet R, editors. Generalised epilepsy. Neurobiological
approaches. Boston: Birkhauser; 1990. p. 355—67.
36. Tang Y, Glauser TA, Gilbert DL, Hershey AD, Privitera MD,
Ficker DM, et al. Valproic acid blood genomic expression
patterns in children with epilepsy a pilot study. Acta Neurol
Scand 2004;109:159—68.
